ORGANOGENESIS HOLDINGS INC. Preferred Stock Dividends, Income Statement Impact
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Preferred Stock Dividends, Income Statement Impact of $2.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2026-08-06
- ORGANOGENESIS HOLDINGS INC. preferred stock dividends, income statement impact for the quarter ending 2026-06-30 was $2.90M, a 8.24% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. preferred stock dividends, income statement impact for the quarter ending 2026-03-31 was $2.84M, a 8.26% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. preferred stock dividends, income statement impact for the quarter ending 2025-12-31 was $2.79M, a 101.15% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. preferred stock dividends, income statement impact for the quarter ending 2025-09-30 was $2.73M.
- ORGANOGENESIS HOLDINGS INC. preferred stock dividends, income statement impact for fiscal 2025 was $10.83M, a 681.39% increase from fiscal 2024.
- ORGANOGENESIS HOLDINGS INC. preferred stock dividends, income statement impact for fiscal 2024 was $1.39M.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.90M 10-Q · filed 2026-08-06 | $5.75M 10-Q · filed 2026-08-06 | $8.53M derived: sum of 3 quarters · filed 2026-08-06 | $11.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.84M 10-Q · filed 2026-05-07 | $5.63M derived: sum of 2 quarters · filed 2026-05-07 | $8.37M derived: sum of 3 quarters · filed 2026-05-07 | $11.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.52M derived: sum of 2 quarters · filed 2026-02-26 | $8.20M derived: sum of 3 quarters · filed 2026-08-06 | $10.83M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.73M 10-Q · filed 2025-11-06 | $5.42M derived: sum of 2 quarters · filed 2026-08-06 | $8.04M 10-Q · filed 2025-11-06 | $9.43M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.68M 10-Q · filed 2026-08-06 | $5.31M 10-Q · filed 2026-08-06 | $6.69M derived: sum of 3 quarters · filed 2026-08-06 | $6.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.63M 10-Q · filed 2026-05-07 | $4.01M derived: sum of 2 quarters · filed 2026-05-07 | $4.01M derived: sum of 3 quarters · filed 2026-05-07 | $4.01M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.39M derived: sum of 2 quarters · filed 2026-02-26 | $1.39M derived: sum of 3 quarters · filed 2026-02-26 | $1.39M 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |